Hyderabad, September 21, 2016: Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar®(paricalcitol) Injection in the United States market approved by the U.S. Food & Drug Administration (USFDA).
The Zemplar® brand and generic had U.S. sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.
Dr. Reddy’s Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.
Zemplar® is a registered trademark of ABBVIE Inc.
*IMS National Sales Perspective: Retail and Non-Retail MAT July 2016
RDY-0916-132
Corporate Comm India (CCI Newswire)
